Related Experiment Video
Updated: Sep 30, 2026
Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Raloxifene treatment increases plasma levels of beta-endorphin in postmenopausal women: a randomized,
Simone J M Neele1, Reinder Evertz, Andrea R Genazzani
1Department of Endocrinology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
Objective:
To evaluate the effect of the selective estrogen receptor modulator raloxifene hydrochloride (Evista, Eli Lilly and Company, Indianapolis, IN) on plasma levels of beta-endorphin, and to determine whether beta-endorphin levels and menopausal symptoms are related.
Design:
A randomized, double-blind, placebo-controlled pilot study.
Setting:
Endocrinology outpatient department.
Patient(S):
Forty postmenopausal women.
Intervention(S):
The women received raloxifene, 60 mg/d, or placebo for 3 months. A questionnaire on climacteric symptoms was administered before and after treatment.
Main Outcome Measure(S):
Circulating levels of beta-endorphin, climacteric symptom score, and correlation with beta-endorphin levels.
Result(S):
Raloxifene treatment significantly increased levels of beta-endorphin and did not significantly affect climacteric symptoms, with the exception of worsening vasomotor symptoms. No significant relation was seen between plasma levels of beta-endorphin and climacteric symptoms.
Conclusion(S):
Raloxifene modulates plasma levels of beta-endorphin without concomitantly relieving climacteric symptoms, as seen with hormone replacement therapy.
